Human angiotensin‐converting enzyme 2 (ACE2) is the primary receptor for SARS‐CoV‐2 cell entry and recombinant ACE2 variants have great therapeutic potential to treat or prevent COVID‐19. Here, ACE2 is linked to COVID-19.